Compugen - CGEN Stock Forecast, Price & News

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Compugen Trading Up 1.4 %

Shares of NASDAQ:CGEN opened at $1.48 on Tuesday. The stock has a fifty day simple moving average of $1.83 and a two-hundred day simple moving average of $2.46. Compugen has a 12-month low of $1.39 and a 12-month high of $7.48.

Compugen (NASDAQ:CGEN - Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. During the same period in the prior year, the business posted ($0.11) earnings per share. Research analysts predict that Compugen will post -0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. JMP Securities lowered their target price on Compugen from $8.00 to $4.00 and set a "market outperform" rating for the company in a research note on Monday. Jefferies Financial Group cut Compugen from a "buy" rating to a "hold" rating and set a $2.00 target price for the company. in a research note on Friday. StockNews.com cut Compugen from a "hold" rating to a "sell" rating in a research note on Monday. Finally, Oppenheimer lowered their target price on Compugen from $14.00 to $12.00 and set an "outperform" rating for the company in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $6.75.